Small Molecules

07 Apr 2017 AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix
07 Apr 2017 BlackThorn Therapeutics Announces Results of Preclinical Study of BTRX-335140, Demonstrating Therapeutic Potential in Modulating Brain Circuits Commonly Dysregulated in Neurobehavioral Disorders
07 Apr 2017 Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
06 Apr 2017 Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
06 Apr 2017 Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
06 Apr 2017 Zavante Therapeutics' ZOLYD™ Met Primary Endpoint In Pivotal ZEUS Study For Treatment Of Complicated Urinary Tract Infections
05 Apr 2017 Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting
05 Apr 2017 Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
05 Apr 2017 Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib and its Prodrug, TP-1287, at AACR 2017
05 Apr 2017 Ignyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting
05 Apr 2017 Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
05 Apr 2017 Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
04 Apr 2017 Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers
04 Apr 2017 Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting
04 Apr 2017 VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
04 Apr 2017 U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
04 Apr 2017 Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary
04 Apr 2017 Intensity Therapeutics Reports That INT230-6 Induces Protective T-Cell Immunity in Preclinical Models
04 Apr 2017 CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017
04 Apr 2017 H3 Biomedicine Presents New Data from Its RNA Splicing Platform at AACR
04 Apr 2017 Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARα Agonist, for Genomically Defined AML and MDS Patients
04 Apr 2017 Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
04 Apr 2017 Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
04 Apr 2017 TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
03 Apr 2017 bene-Arzneimittel Receives Positive CHMP Opinion for elmiron® for the Treatment of Bladder Pain Syndrome in the European Union

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing